Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07339553 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer.

Name: Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer. — clinical trial record (NCT07339553)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2

SponsorPeking University Third Hospital

Started2026-01-04

View on ClinicalTrials.gov ↗

Amendment history

2026-01-17

Study Identification, Study Status v1

Study title+19 characters

Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of ~~Platinum-Sensitive~~Patients With Advanced or Recurrent Epithelial Ovarian Cancer.

2026-01-05

Original filing

Peking University Third Hospital

219 trials monitored

See 3 trials at risk

Ovarian Cancer

1,239 trials monitored

See 74 trials at risk

This study evaluates the efficacy and safety of Zeprumetostat in combination with Fuzuloparib for the treatment of patients with advanced or recurrent ovarian epithelial carcinoma, with the primary endpoint being Objective Response Rate (ORR).

Trial Details

NCT Number	NCT07339553
Lead Sponsor	Peking University Third Hospital
Conditions	Ovariancancer, Platinum-sensitive Recurrent
Enrollment	30 participants
Start Date	2026-01-04
Primary Completion	2029-01-30 (estimated)
Study Completion	2029-02-26 (estimated)
Updated on ClinicalTrials.gov	2026-01-21